MedTrace Logo

A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients

NCT04347174 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-01-27

No results posted yet for this study

Summary

The trial is randomized, blinded, two arms, active comparator controlled, clinical trial to evaluate the safety and efficacy of Mycobacterium w in combination with standard care as per hospital practice versus standard care alone in critically ill adult patients suffering from COVID-19 infection.

Conditions

Interventions

DRUG

Suspension of heat killed (autoclaved) Mycobacterium w

Patients will be randomized to receive either Mycobacterium w in combination with standard care as per hospital practice or standard care alone in COVID-19 as per hospital practice.

DRUG

Placebo

All patients will continue to receive standard therapy as per hospital practice till considered requisite by the treating physician

Sponsors & Collaborators

  • Council of Scientific and Industrial Research, India

    collaborator OTHER_GOV

  • Cadila Pharnmaceuticals

    lead INDUSTRY

Principal Investigators

  • Anil Avhad, MBBS · Cadila Pharmaceuticals Limited

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-30
Primary Completion
2020-08-10
Completion
2020-08-21

Countries

  • India

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04347174 on ClinicalTrials.gov